Relmada Therapeutics (RLMD) Other financing activities (2014 - 2026)

Relmada Therapeutics (RLMD) has 5 years of Other financing activities data on file, last reported at $65651.0 in Q1 2026.

• Other financing activities for Q1 2026 came in at $65651.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $238138.0 (changed N/A YoY), and the FY2025 annual result was $73021.0, down 74.56% from the prior year.
• Other financing activities fell to $65651.0 in Q1 2026 per RLMD's latest filing, from $172487.0 in the prior quarter.
• Over five years, Other financing activities peaked at $12.3 million in Q2 2022 and troughed at -$77.5 million in Q4 2022.
• A 4-year average of -$3.7 million and a median of $4.3 million in 2022 frame the typical range for Other financing activities.
• On a YoY basis, Other financing activities climbed as much as 100.51% in 2024 and fell as far as 99.78% in 2024.
• A 4-year view of Other financing activities shows it stood at -$77.5 million in 2022, then soared by 56.37% to -$33.8 million in 2023, then jumped by 100.51% to $172487.0 in 2024, then sank by 61.94% to $65651.0 in 2026.
• Business Quant data shows RLMD's Other financing activities at $65651.0 in Q1 2026, $172487.0 in Q4 2024, and $89601.0 in Q3 2024.